138 related articles for article (PubMed ID: 32717234)
41. The National Surgical Quality Improvement Program risk calculator does not adequately stratify risk for patients with clinical stage I non-small cell lung cancer.
Samson P; Robinson CG; Bradley J; Lee A; Broderick S; Kreisel D; Krupnick AS; Patterson GA; Puri V; Meyers BF; Crabtree T
J Thorac Cardiovasc Surg; 2016 Mar; 151(3):697-705.e1. PubMed ID: 26410001
[TBL] [Abstract][Full Text] [Related]
42. In Response to Treatment Outcomes in Stage I Lung Cancer: A Comparison of Surgery and Stereotactic Body Radiation Therapy.
Puri V; Robinson CG
J Thorac Oncol; 2016 May; 11(5):e65-e66. PubMed ID: 27131297
[No Abstract] [Full Text] [Related]
43. Central versus Peripheral Tumor Location: Influence on Survival, Local Control, and Toxicity Following Stereotactic Body Radiotherapy for Primary Non-Small-Cell Lung Cancer.
Park HS; Harder EM; Mancini BR; Decker RH
J Thorac Oncol; 2015 May; 10(5):832-837. PubMed ID: 25634007
[TBL] [Abstract][Full Text] [Related]
44. Stereotactic body radiation therapy for lung cancer: achievements and perspectives.
Hiraoka M; Matsuo Y; Takayama K
Jpn J Clin Oncol; 2010 Sep; 40(9):846-54. PubMed ID: 20670962
[TBL] [Abstract][Full Text] [Related]
45. Value of dual time point F-18 FDG-PET/CT imaging for the evaluation of prognosis and risk factors for recurrence in patients with stage I non-small cell lung cancer treated with stereotactic body radiation therapy.
Satoh Y; Nambu A; Onishi H; Sawada E; Tominaga L; Kuriyama K; Komiyama T; Marino K; Aoki S; Araya M; Saito R; Maehata Y; Oguri M; Araki T
Eur J Radiol; 2012 Nov; 81(11):3530-4. PubMed ID: 22178287
[TBL] [Abstract][Full Text] [Related]
46. A wedge is still better than stereotactic body radiation therapy in the national cancer database.
Odeh AM; Perez-Tamayo RA; Abdelsattar ZM
J Thorac Cardiovasc Surg; 2024 Apr; 167(4):e100-e101. PubMed ID: 37747399
[No Abstract] [Full Text] [Related]
47. The impact of tumor size on outcomes after stereotactic body radiation therapy for medically inoperable early-stage non-small cell lung cancer.
Allibhai Z; Taremi M; Bezjak A; Brade A; Hope AJ; Sun A; Cho BC
Int J Radiat Oncol Biol Phys; 2013 Dec; 87(5):1064-70. PubMed ID: 24210082
[TBL] [Abstract][Full Text] [Related]
48. Improving outcomes for high-risk patients with early-stage non-small-cell lung cancer: insights from population-based data and the role of stereotactic ablative radiotherapy.
Palma DA; Senan S
Clin Lung Cancer; 2013 Jan; 14(1):1-5. PubMed ID: 22846581
[No Abstract] [Full Text] [Related]
49. Long-Term Outcome of Surgery or Stereotactic Radiotherapy for Lung Oligo-recurrence.
Niibe Y; Jingu K; Onishi H
J Thorac Oncol; 2017 Nov; 12(11):e191. PubMed ID: 29074214
[No Abstract] [Full Text] [Related]
50. Impact of Tumor Size on Local Control and Pneumonitis After Stereotactic Body Radiation Therapy for Lung Tumors.
Parker SM; Siochi RA; Wen S; Mattes MD
Pract Radiat Oncol; 2019 Jan; 9(1):e90-e97. PubMed ID: 30267899
[TBL] [Abstract][Full Text] [Related]
51. Stereotactic radiosurgery for lung tumors.
Whyte RI
Semin Thorac Cardiovasc Surg; 2010; 22(1):59-66. PubMed ID: 20813318
[TBL] [Abstract][Full Text] [Related]
52. Phase 2 Study of Stereotactic Body Radiation Therapy and Stereotactic Body Proton Therapy for High-Risk, Medically Inoperable, Early-Stage Non-Small Cell Lung Cancer.
Nantavithya C; Gomez DR; Wei X; Komaki R; Liao Z; Lin SH; Jeter M; Nguyen QN; Li H; Zhang X; Poenisch F; Zhu XR; Balter PA; Feng L; Choi NC; Mohan R; Chang JY
Int J Radiat Oncol Biol Phys; 2018 Jul; 101(3):558-563. PubMed ID: 29680255
[TBL] [Abstract][Full Text] [Related]
53. [Stereotactic radiotherapy for early non-small cell lung cancer].
Xing LG; Kong FM; Yu JM
Zhonghua Zhong Liu Za Zhi; 2012 Sep; 34(9):641-4. PubMed ID: 23159074
[No Abstract] [Full Text] [Related]
54. Stereotactic body radiation therapy for inoperable lung cancer.
Rusthoven KE; Pugh TJ
JAMA; 2010 Jun; 303(23):2354-5; author reply 2355. PubMed ID: 20551403
[No Abstract] [Full Text] [Related]
55. First Reported Case of Postirradiation Pseudosclerodermatous Panniculitis After Stereotactic Body Radiation Therapy for the Treatment of Non-Small Cell Lung Cancer.
Sachsman SM; Haydel DM; Kim CN
Am J Dermatopathol; 2016 Feb; 38(2):144-7. PubMed ID: 26825159
[TBL] [Abstract][Full Text] [Related]
56. Surgical treatment of local recurrence after stereotactic body radiotherapy for primary and metastatic lung cancers.
Neri S; Takahashi Y; Terashi T; Hamakawa H; Tomii K; Katakami N; Kokubo M
J Thorac Oncol; 2010 Dec; 5(12):2003-7. PubMed ID: 21102262
[TBL] [Abstract][Full Text] [Related]
57. Stereotactic body radiotherapy for central lung tumors.
Rowe BP; Boffa DJ; Wilson LD; Kim AW; Detterbeck FC; Decker RH
J Thorac Oncol; 2012 Sep; 7(9):1394-9. PubMed ID: 22843088
[TBL] [Abstract][Full Text] [Related]
58. Stereotactic body radiation therapy versus video-assisted thoracoscopic surgery in stage I lung cancer: Honesty in the face of uncertainty.
Kidane B
J Thorac Cardiovasc Surg; 2018 Jan; 155(1):365-366. PubMed ID: 28916217
[No Abstract] [Full Text] [Related]
59. Early-Stage Lung Cancer, Surgery, and Stereotactic Body Radiation Therapy: Quality of Life.
Videtic GM
Int J Radiat Oncol Biol Phys; 2016 Dec; 96(5):927-930. PubMed ID: 27869093
[No Abstract] [Full Text] [Related]
60. 7-year follow-up after stereotactic ablative radiotherapy for patients with stage I non-small cell lung cancer: Results of a phase 2 clinical trial.
Sun B; Brooks ED; Komaki RU; Liao Z; Jeter MD; McAleer MF; Allen PK; Balter PA; Welsh JD; O'Reilly MS; Gomez D; Hahn SM; Roth JA; Mehran RJ; Heymach JV; Chang JY
Cancer; 2017 Aug; 123(16):3031-3039. PubMed ID: 28346656
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
